Peptide Manufacturing
Our peptide synthesis development and manufacturing services support a broad range of peptide therapeutics, including GLP-1 analogs, recombinant peptides, and other high-volume and complex-structure peptides, from development through commercial GMP supply, providing flexible solutions tailored to your program requirements.
Peptide Types
From simple peptides to complex, conjugated, and long peptides, our development and manufacturing capabilities span the broad range of peptide therapeutics. Our flexible approach allows us to work with the platform best suited to your program, including our proprietary AJIPHASE™ and CORYNEX™ technologies.
Linear Peptides
Most peptide therapeutics can be manufactured using AJIPHASE™, our proprietary Tag-Assisted Liquid-Phase Peptide Synthesis (LPPS) platform. By performing synthesis in solution using a soluble tag, AJIPHASE™ supports efficient scale-up, broad sequence flexibility, and GMP manufacturing.
Cyclic Peptides
Cyclization chemistry for constrained peptides — head-to-tail, side-chain, and disulfide cyclization. Confirm specific chemistries in scope with the team.
Modified Peptides
AJIPHASE™ supports the manufacture of peptides with a wide range of chemical modifications, including lipidation, PEGylation, conjugation, and non-natural amino acids. Each process is designed around the properties of the molecule to deliver consistent product quality, scalability, and reliable commercial supply.
Complex Sequences
AJIPHASE™ supports cyclic peptides, stapled peptides, conjugated peptides, and other modified sequences. Manufacturing strategies are tailored to the specific requirements of each molecule to optimize quality, scalability, and supply reliability.
GLP-1 Analogs
AJIPHASE™ provides a scalable manufacturing solution for GLP-1 analogs and other high-volume peptide therapeutics. For selected molecules, CORYNEX™ recombinant expression technology can also be incorporated into a hybrid manufacturing strategy.
Long-Chain Peptides
Scalable and sustainable manufacturing of long-chain peptides and peptide fragments. Chemical, microbial, and combined approaches enable flexible manufacturing with high purity and productivity. Applicable to GLP-1-related and other long-acting peptides.
Removing Barriers to Peptide Development with Proprietary Technologies
Flexible options based on the specific needs of each program: from liquid-phase synthesis with AJIPHASE™ to recombinant peptide expression with CORYNEX™. Platform selection depends on peptide length, sequence composition, modifications, and commercial supply requirements. For some programs, both technologies can be combined as part of a hybrid manufacturing strategy.
GLP-1: Meeting the Demand for Metabolic Therapeutics
AJIPHASE™ supports GLP-1 manufacturing through fragment-based synthesis strategies that improve process efficiency and enable scale-up beyond conventional solid-phase approaches. For selected molecules, fermentation-based technologies, CORYNEX™ recombinant expression can also be incorporated as part of a hybrid manufacturing strategy, providing additional flexibility to optimize cost, scalability, and long-term supply.
Analytical and Quality Systems
We provide integrated analytical development, quality control, and CMC support through dedicated in-house teams. Capabilities include method development and validation, impurity characterization, stability studies, and release testing using advanced analytical technologies. Combined with robust GMP quality systems and regulatory expertise, these capabilities support analytical and control strategies from development through commercial supply.
20+
Years of Peptide Synthesis Expertise
5
Sites Across Belgium, India, & Japan
>90%
Organic Solvent Reduction vs. SPPS
Development and Manufacturing Facilities
Five sites across Belgium, India, and Japan providing flexible approaches to fit the unique needs of your specialized programs.
Balen, Belgium
Balen supports commercial GMP peptide manufacturing and continuous flow chemistry technologies. Processes built for scale-up, sustainability, and long-term supply of peptide therapeutics.
Wetteren, Belgium
Wetteren provides GMP peptide manufacturing capabilities using AJIPHASE™, conventional liquid-phase synthesis, and flow chemistry technologies. The site supports commercial production, scale-up, and long-term supply of peptide therapeutics.
Visakhapatnam, India
Visakhapatnam provides liquid-phase peptide synthesis. The site supports commercial production, scale-up, and long-term supply of peptide therapeutics.
Kawasaki, Japan
CORYNEX™ strain, process, and analytical development is performed in-house at our facility in Kawasaki, Japan, with GMP manufacturing carried out by qualified partner CDMOs under our technical oversight.
Tokai, Japan
Tokai serves as the center for AJIPHASE™ process development, analytical development, technology transfer, and GMP manufacturing. Integrated development, quality, and manufacturing teams support programs from early development through commercial supply.
Let’s Discuss Your Peptide Program
Chemical synthesis to commercial scale. Recombinant expression for endotoxin-free peptides. Specialized service tailored to each program.
Frequently Asked Questions
What peptide types can Ajinomoto Bio-Pharma Services manufacture?
Ajinomoto Bio-Pharma Services supports the manufacture of linear, long-chain, cyclic, stapled, and other complex peptide therapeutics, including GLP-1 analogs. Manufacturing approaches are tailored to each molecule and program, with the flexibility to work across peptide manufacturing technologies, including our proprietary AJIPHASE™ liquid-phase synthesis and CORYNEX™ recombinant expression technologies.
What is the difference between AJIPHASE™ and CORYNEX™ for peptides?
AJIPHASE™ uses Tag-Assisted Liquid-Phase Peptide Synthesis, while CORYNEX™ uses recombinant expression technology. Platform selection depends on peptide length, sequence composition, modifications, and commercial supply requirements. For some programs, both technologies can be combined as part of a hybrid manufacturing strategy.
Can Ajinomoto Bio-Pharma Services manufacture GLP-1 peptides at commercial scale?
Yes, Ajinomoto Bio-Pharma Services can support the manufacture of GLP-1 peptides at commercial scale. AJIPHASE™ supports scalable manufacturing of GLP-1 analogs. Fragment-based synthesis strategies enable efficient production of peptides of approximately 40 amino acids, while CORYNEX™ technology can be incorporated into hybrid manufacturing approaches for selected programs.
What is Ajinomoto Bio-Pharma Services’ maximum peptide synthesis scale?
At Ajinomoto Bio-Pharma Services, AJIPHASE™ can demonstrate GMP peptide manufacturing at scales exceeding 100 kg per batch using chemical reactors. Achievable scale depends on peptide characteristics and manufacturing equipment. CORYNEX™ recombinant expression technology is also available for selected high-volume peptides.
Does Ajinomoto Bio-Pharma Services support peptide-PMO conjugate (PPMO) synthesis?
Yes. Ajinomoto Bio-Pharma Services offers integrated peptide and oligonucleotide manufacturing capabilities, providing a single partner for PPMO development, manufacturing, and supply.